DUBLIN--(BUSINESS WIRE)--The "Idiopathic Pulmonary Fibrosis - Pipeline Insights, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Idiopathic Pulmonary Fibrosis - Pipeline Insights, 2018 Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
- Product Description
- Research and Development
- Product Development Activities
Companies Mentioned
- Asahi Kasei Pharma Corporation
- Celgene Corporation
- Hoffmann-La Roche
- Kadmon Corporation
- Merck & Co., Inc.
- Galapagos NV
- Beijing Tide Pharmaceutical Co., Ltd.
- Biogen Inc.
- Bristol-Myers Squibb
- Chong Kun Dang Pharmaceutical
- FibroGen
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/f7qt4l/idiopathic?w=4
